Clinical Trials Logo

Clinical Trial Summary

Bronchiectasis is characterized pathologically by permanent bronchial dilatation and airway inflammation. The pathogenesis of the disease and the inflammatory, infective and molecular drivers of disease progression are not fully understood. The concept of "treatable traits" was proposed as biomarker-directed approach, based on the recognition of clinical phenotype and endotypes, help to personalized treatment options. Airway microbiota, including bacteria, NTM and fungus, have important but different inflammatory process in bronchiectasis. Our study will provide a new concept that airway microbiota might involve in the airway and systemic inflammation, mucus hypersecretion, as well as the airway damage, remodeling, and frequent exacerbations in bronchiectasis, thus leading to the deterioration of disease severity. Bronchiectasis remains a major cause of respiratory morbidity and treatment is generally only partly successful. Our study will give more clues about the mechanisms on the inflammatory pathway and the probably different response among patients with different isolated microbiota from airways.


Clinical Trial Description

Bronchiectasis is characterized pathologically by permanent bronchial dilatation and airway inflammation, and clinically by productive cough, hemoptysis and periodic infectious exacerbations. The pathogenesis of the disease and the inflammatory, infective and molecular drivers of disease progression are not fully understood. Current available therapeutic options have shown only a modest impact on disease outcomes in randomized clinical trials. The concept of "treatable traits" was proposed as biomarker-directed approach, based on the recognition of clinical phenotype and endotypes, help to personalized treatment options. Potential treatable traits of airways disease into four broad categories: pulmonary, extra-pulmonary, etiological, and behavior and lifestyle treatable traits. Airway microbiota, including bacteria, NTM and fungus, have important but different inflammatory process in bronchiectasis. Our study will provide a new concept that airway microbiota might involve in the airway and systemic inflammation, mucus hypersecretion, as well as the airway damage, remodeling, and frequent exacerbations in bronchiectasis, thus leading to the deterioration of disease severity. Bronchiectasis remains a major cause of respiratory morbidity and treatment is generally only partly successful. Our study will give more clues about the mechanisms by which the immunomodulatory medications (macrolides) on the inflammatory pathway and the probably different response among patients with different isolated microbiota from airways. Thus, our results will not only shed light on the airway microbiota inflammatory mechanisms responsible for disease severity, but also provide a new therapeutic direction. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05068518
Study type Observational
Source Chang Gung Memorial Hospital
Contact Chun Yu Lin, MD
Phone 886-3-3281200
Email [email protected]
Status Not yet recruiting
Phase
Start date October 1, 2021
Completion date December 31, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT04142827 - The Effect of Long Term Therapy With High Flow Humidification Compared to Usual Care in Patients With Bronchiectasis (BX) N/A
Not yet recruiting NCT04509661 - Efficacy and Safety of Inhaled Bronchodilator in Non-CF Bronchiectasis With Airflow Limitation Phase 4
Recruiting NCT03715322 - Tobramycin in Bronchiectasis Colonized With Pseudmonas Aeruginosa Phase 3
Active, not recruiting NCT03696290 - Value of Inhaled Treatment With Aztreonam Lysine in Bronchiectasis Phase 2
Recruiting NCT04658277 - Effect of Long Term Clarithromycin for Prevention of Exacerbations in Non-cystic Fibrosis Bronchiectasis in Asian Populations N/A
Active, not recruiting NCT04744220 - Evaluation of the Effect of Yoga Training on Functional Capacity and Quality of Life in Patients With Bronchiectasis N/A
Not yet recruiting NCT04987827 - Investigating the Clinical Features and Prognosis of Bronchiectasis Adult Patients
Recruiting NCT03791086 - The BRIDGE Study - Bronchiectasis Research Involving Databases, Genomics and Endotyping
Completed NCT04234789 - Predictors of Physical Activity Performance and Dynamic Hyperinflation in Patients With Bronchiectasis N/A
Recruiting NCT04865861 - The Characteristic of Airway Microbiome Profiling of COPD-bronchiectasis Overlap Patients and Its Association With Acute Exacerbation
Recruiting NCT04742270 - Home Airway Clearance in Patients With Bronchiectasis (Home-Care Bronchiectasis) N/A
Completed NCT03125174 - Characterization of Airway Mucus in Bronchiectasis Patients and Healthy Controls N/A
Recruiting NCT04102774 - Effect of AIRVO Heated Humidification in Bronchiectasis N/A
Completed NCT03383939 - Inhaled A1AT in Adult Stable Bronchiectasis N/A
Recruiting NCT04574050 - SELF-BREATHE RCT for Chronic Breathlessness N/A
Not yet recruiting NCT04511897 - Efficacy and Safety of An'Ningpai Expectorant in Non-CF Bronchiectasis Phase 4
Completed NCT03643302 - Airway Clearance and Bronchoalveolar Lavage for Bronchiectasis Patients With Exacerbation
Recruiting NCT03988816 - Effect of Roflumilast on Quality of Life, Lung Function and Mucus Properties in Patients With Bronchiectasis Phase 2
Not yet recruiting NCT03177889 - Lung Dispersing, Turbid Descending and Gut Clearing Decoction for Bronchiectasis N/A
Recruiting NCT03467035 - Role of NLRP3 Inflammasone and Hypoxia in the Severity of Osteoporosis in Patients With Bronchiectasis N/A